From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
MDA-MB-231
SUM-149
siCDK11
siCK2
CDK11
0.59
1.36
0.98
CK2α
2.09
0.15
1.37
0.13
CK2α′
1.48
0.19
1.18
0.16